article thumbnail

Patent Grant Total 2023

Patently-O

by Dennis Crouch The US Patent and Trademark Office (USPTO) issued a total of 312,100 utility patents in the calendar year 2023. This marks the fourth consecutive year of decline in the number of issued patents. In fact, numbers from US-applicants increased over the past year.

Patent 107
article thumbnail

2023 Patent Litigation: A Year In Review

IP Law 360

Attorneys filed fewer patent suits in district courts in 2023 than in any year for more than a decade, and the amount of America Invents Act petitions at the Patent Trial and Appeal Board fell to a 10-year low as well. in 2023, with the Eastern District of Texas overtaking it.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Best Inventions of 2023 are a Cross Section of Brilliant Ideas from a Wide Range of Sources

IP Close Up

“The Best Inventions for 2023,” Time magazine’s revealing overview of patented breakthrough solutions to life’s challenges, illustrates the breadth of industries, technologies and businesses building Continue reading

article thumbnail

Crystal clear? G 2/21 applied to polymorph patents (T 1994/22)

The IPKat

The decision of the Enlarged Board of Appeal (EBA) in G 2/21 on the use of post-published evidence to support patentability, was self-confessedly vague and open to interpretation ( IPKat ). The patent protecting the commercialised polymorph of a drug may therefore provide valuable exclusivity.

Invention 112
article thumbnail

The criteria for the novelty and inventive step of pharmaceutical selection inventions (T 1356/21)

The IPKat

The recent Board of Appeal decision in T 1356/21 covered a number of interesting legal points in the field of pharmaceutical patents. The case related to the novelty and inventive step of a second medical use claim. However, it is possible to patent a "substance or composition for use " in a method of treatment.

Invention 117
article thumbnail

UPC takes strong stance on therapeutic antibody inventions (Sanofi v Amgen, UPC_CFI_1/202)

The IPKat

The UPC Central Division also takes a strong stance on the patentability of therapeutic antibody inventions in Europe. The decision of the UPC confirms that the US and European approaches to antibody inventions are diametrically opposed. The decision is not just remarkable for being the first decision of its kind.

article thumbnail

Guidance on Patenting Inventions with AI Contributions

Patently-O

The following are my remarks given on April 25, 2023 to the USPTO as part of their AI listening session: by Dennis Crouch Members of the USPTO, and fellow participants of this AI Listening Session, thank you for inviting me here today and for taking time to consider these important issues.

Invention 125